KRAS G12V
Clinical trials for KRAS G12V explained in plain language.
Never miss a new study
Get alerted when new KRAS G12V trials appear
Sign up with your email to follow new studies for KRAS G12V, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Matched conditions: KRAS G12V
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental vaccine trains immune system to fight Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…
Matched conditions: KRAS G12V
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC